No Data
Shareholder Bai Ying of eyebright medical technology (beijing) co., ltd. (688050.SH) intends to reduce shareholding by no more than 1.5%.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced that shareholder Bai Ying, who holds 5.63% of the shares, plans to conduct a block trade...
688050 Aibo Healthcare 2024 Third Quarter Report
eyebright medical technology (beijing) co., ltd. (688050.SH): The net income for the first three quarters was 0.318 billion yuan, a year-on-year increase of 26.04%.
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. (688050.SH) announced on October 29th that in the first three quarters of 2024, it achieved a total operating income of 1.075 billion yuan, a year-on-year increase of 60.94%; net income attributable to shareholders of the parent company was 0.318 billion yuan, a year-on-year increase of 26.04%; and the basic earnings per share was 1.68 yuan.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): It is planned to raise funds by no more than 0.3 billion yuan through a private placement.
Gelonghui October 29th, eyebright medical technology (beijing) co., ltd. (688050.SH) announced the stock issuance plan for 2024 to specific entities through a simple process. The total amount of funds raised through this simple process for issuing stocks will not exceed 300 million yuan (including the base amount). The net funds raised after deducting issuance expenses will be used for the following projects: the construction project of contact lenses and injection molding production line, and supplementary working capital.
eyebright medical technology (beijing) co., ltd. (688050.SH): the crystalline artificial crystalline (PR) product is still in the approval process.
Gelonghui October 16th | Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) stated on the investor interaction platform that the company's intraocular lens artificial lens (PR) product is still in the approval process, not yet certified for listing, and it is inconvenient to disclose the business plan. The company will continue to fully utilize its own technological and academic promotion advantages, as well as the synergies of various business lines, to expand brand influence, enhance recognition at the level of doctors, patients, and consumers, continuously consolidate and increase market share.
Eyebright Medical Technology (Beijing) Co., Ltd.'s semi-annual report for 2024
No Data
